Clinical Study Results
Research Sponsor: MedImmune Ltd., a wholly owned subsidiary of AstraZeneca
Drug Studied: MEDI0382, also known as cotadutide
Study Title: A study to learn about the safety of MEDI0382 in participants with type 2 diabetes who are overweight or obese

Thank you!
Thank you for taking part in the clinical study for the study drug MEDI0382, also called cotadutide. You and all of the participants helped researchers learn more about MEDI0382 to help people with type 2 diabetes mellitus, also called T2DM. MedImmune Ltd., an AstraZeneca company, sponsored this study and thinks it is important to share the results of the study with you and the public. An independent non-profit organization called CISCRP helped prepare this summary of the study results for you. We hope it helps you understand and feel proud of your important role in medical research.

If you participated in the study and have questions about the results, please speak with the doctor or staff at your study site.

What is happening with the study now?
The participants were in the study for about 4 months, but the entire study took about 5 months to finish. The study started in January 2019 and ended in May 2019.
This study included a total of 20 participants in Germany.
The sponsor reviewed the data collected when the study ended and created a report of the results. This is a summary of that report.